Several other ADCs targeting molecules such as EGFR, folate receptor 1 (FOLR1), receptor tyrosine kinase-like orphan receptor 2 (ROR2) and AXL receptor tyrosine kinase (AXL) are currently under investigation for the treatment of NSCLC, but data on intracranial activity are not yet available (Table A1). This evidence concerns the gene ROR2 and non-small cell lung carcinoma.